Pharmacodynamic Evaluation of the Gexia Zhuyu Decoction in the Treatment of NAFLD and the Molecular Mechanism Underlying the TRPM4 Pathway Regulation

Table 2

Serum biochemical indicators after Gexia Zhuyu decoction administration.

nmol/L

NAFL

NASH

Nonalcoholic fatty liver fibrosis

CG

CG + GXZY

MG

GXZY

CG

CG + GXZY

MG

GXZY

CG

CG + GXZY

MG

GXZY

Serum ALT

50.0 ± 0.05

48.32 ± 1.13

122.3 ± 8.35

95.26 ± 6.03

37.35 ± 6.16

36.68 ± 5.58

235.57 ± 7.32

202.11 ± 7.39

39.32 ± 1.45

42.05 ± 1.62

224.51 ± 18.16

127.53 ± 10.12

Serum AST

105.55 ± 5.30

103.26 ± 4.83

196.28 ± 3.47

165.52 ± 5.02

105.63 ± 6.49

108.05 ± 6.37

298.51 ± 11.16

254.53 ± 10.12

86.35 ± 9.16

84.68 ± 5.58

285.57 ± 15.32

152.11 ± 7.39

Serum TG

0.73 ± 0.12

0.75 ± 0.09

1.75 ± 0.08

1.23 ± 0.16

0.91 ± 0.21

0.89 ± 0.22

1.97 ± 0.13

1.45 ± 0.14

0.95 ± 0.21

0.91 ± 0.24

0.57 ± 0.17

0.78 ± 0.25

Liver TG

0.85 ± 0.12

0.82 ± 0.09

1.65 ± 0.29

1.12 ± 0.06

0.85 ± 0.12

0.82 ± 0.09

2.05 ± 0.08

1.69 ± 0.16

3.23 ± 0.30

3.57 ± 0.32

7.59 ± 0.34

5.41 ± 0.25

Compared to the model group, ^∗∗, ^∗.